Cardiovascular safety findings in patients with rheumatoid arthritis treated with tofacitinib, an oral Janus kinase inhibitor

Article ID	Journal	Published Year	Pages	File Type
5584054	Seminars in Arthritis and Rheumatism	2016	11 Pages	PDF

Abstract

Tofacitinib was associated with a low incidence of CV events in a large Phase 3 program, including LTE studies. Further long-term studies are underway.

Keywords

patient-years LTE ChF HDL-C DMARD ACR MTX Q2W LDL-C Inadequate response NSAID MACE DBP ESR long-term extension csDMARD Myocardial infarction apo apolipoprotein major adverse cardiovascular events Disease-modifying antirheumatic drug twice daily erythrocyte sedimentation rate adverse event Non-steroidal anti-inflammatory drug diastolic blood pressure Blood pressure cardiovascular high-density lipoprotein cholesterol Methotrexate congestive heart failure C-reactive protein CRP BID American College of Rheumatology Low-density lipoprotein cholesterol

Related Topics

Health Sciences Medicine and Dentistry Anesthesiology and Pain Medicine

Cardiovascular safety findings in patients with rheumatoid arthritis treated with tofacitinib, an oral Janus kinase inhibitor

Authors

Christina MD, Pierre MD, Miguel A. MD, PhD, Mary MD, Andrea MD, Koshika MD, Jamie PhD, Kenneth MSc, Richard MD, PhD,